STEPHEN DALE - 16 Feb 2023 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role
Chief Medical Officer
Signature
Teresa Bair, Attorney-in-fact for Stephen Dale
Issuer symbol
KURA
Transactions as of
16 Feb 2023
Net transactions value
$0
Form type
4
Filing time
21 Feb 2023, 16:08:20 UTC
Previous filing
31 Jan 2023
Next filing
04 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Award $0 +23,125 +84% $0.000000 50,800 16 Feb 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KURA Option to purchase common stock Award $0 +185,000 $0.000000 185,000 16 Feb 2023 Common Stock 185,000 $11.99 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/24, 1/26/25, 1/26/26 and 1/26/27.
F2 This option vests in 48 equal monthly installments commencing on the grant date.